ACNT vs NVS vs PFE vs ZEUS vs JNJ

For growth investors, Novartis AG (NVS) is the stronger pick with 6.

0% revenue growth year-over-year, versus -57. 9% for Ascent Industries Co. (ACNT). Pfizer Inc. (PFE) offers the better valuation at 19. 3x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Ascent Industries Co. (ACNT) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Pfizer Inc.

(PFE) is the cheapest at 19. 3x versus Johnson & Johnson at 41. 6x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Olympic Steel, Inc. wins at 0. 49x versus Johnson & Johnson's 37. 02x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Novartis AG (NVS) delivered a total return of +94.

0%, compared to -13. 0% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: NVS returned +187. 2% versus PFE's +25. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

01β versus Olympic Steel, Inc. 's 1. 23β — meaning ZEUS is approximately 16321% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Ascent Industries Co. (ACNT) carries a lower debt/equity ratio of 15% versus 80% for Novartis AG — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novartis AG (NVS) is pulling ahead at 6.

0% versus -57. 9% for Ascent Industries Co. (ACNT). On earnings-per-share growth, the picture is similar: Ascent Industries Co. grew EPS 56. 7% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, NVS leads at 8. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novartis AG (NVS) is the more profitable company, earning 25.

6% net margin versus -7. 5% for Ascent Industries Co. — meaning it keeps 25. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31. 2% versus -9. 0% for ACNT. At the gross margin level — before operating expenses — NVS leads at 75. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Olympic Steel, Inc. (ZEUS) is the more undervalued stock at a PEG of 0. 49x versus Johnson & Johnson's 37. 02x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 9x forward P/E versus 20. 8x for Johnson & Johnson — 12. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACNT: 28. 1% to $18. 00.

In this comparison, PFE (6.

6% yield), NVS (2. 6% yield), JNJ (2. 0% yield), ZEUS (1. 2% yield) pay a dividend. ACNT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

01), 2. 0% yield, +142. 4% 10Y return). Both have compounded well over 10 years (JNJ: +142. 4%, ZEUS: +96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ACNT (Basic Materials) and NVS (Healthcare) and PFE (Healthcare) and ZEUS (Basic Materials) and JNJ (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ACNT is a small-cap quality compounder stock; NVS is a large-cap quality compounder stock; PFE is a mid-cap income-oriented stock; ZEUS is a small-cap quality compounder stock; JNJ is a large-cap quality compounder stock. NVS, PFE, ZEUS, JNJ pay a dividend while ACNT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.